A Multicenter, Placebo-controlled, Randomized, Double-blind, Phase II Clinical Trial With Diabetic Neuropathy Patients is Designed to Evaluate the Safety and Efficacy of the DA-9801 Tablet for Neuropathic Pain and to Decide Optimal Dose
Latest Information Update: 29 Jan 2020
At a glance
- Drugs NB 01 (Primary)
- Indications Diabetic neuropathies
- Focus Proof of concept; Therapeutic Use
- Sponsors Dong-A ST
- 14 Apr 2019 Status changed from recruiting to completed.
- 26 Mar 2013 New trial record